The orphan drugs
market growth is fueled by the factors such as extended market exclusivity and government incentives for orphan medicine.
Identify opportunities: Analysis of the leading companies in the orphan drug
space, examining their portfolios and orphan drugs
in their pipelines.
com/research/g8q842/global_orphan) has announced the addition of the "Global Orphan Drug
Market Future Outlook 2020" report to their offering.
The report provides an understanding and analysis of how and why companies enter orphan drugs
6 million in 1987 alone on research and development of orphan drugs
Research: innovative areas of research such as antisense therapy, gene therapy, and cellular therapy in which orphan drugs
are playing a key role.
The FDA's Office of Orphan Drug
Products Development reviews applications for Orphan Drug
status to support development of medicines for underserved patient populations, or rare disorders that affect fewer than 200,000 people in the United States.
In US, the research & development of orphan drugs
is facilitated by public programs, government regulations, and policies.
This report reviews the orphan drug
regulations in 10 Asian countries and discusses various business issues related to orphan drugs
in the region.
The returns on investment from orphan drugs
are expected to help the pharma companies to overcome the impact of revenue loss due to expiry of patents of blockbuster drugs.
With many companies facing the patent cliff, orphan drugs
offer potentially high returns, lower development costs and less intense competition.
The major drivers for companies to increasingly invest in orphan drugs
include government incentives for drug development and strong support from the FDA and EU Commission in special protocols.